CETP (P11597) variants and mutations
CETP (also known as P11597) is a human protein-coding gene encoding a cholesteryl ester transfer protein. It transfers cholesteryl esters and triglycerides between HDL and apoB-containing lipoproteins, strongly influencing circulating lipoprotein composition. Loss-of-function variants can raise HDL cholesterol, while pharmacologic CETP inhibition has been developed to lower atherosclerotic cardiovascular risk. This analysis covers 824 CETP variants and mutations. Of these, 81% have computational variant effect predictions. Disease context includes cholesterol-ester transfer protein deficiency, coronary artery disorder, and metabolic syndrome. Example CETP variants include L2V, L2L, and A3P.
Variant analysis overview
- Gene: CETP
- Protein: P11597
- UniProt accession: P11597
- Organism: Homo sapiens
- Variants analyzed: 824
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 610 unspecified-consequence records; 85 synonymous variants; 101 missense variants; 17 frameshift variants; 5 splice-region variants; 2 stop-gained variants; 2 in-frame deletions; 1 in-frame insertions; 1 substitution
- Prediction scores: 665 variants have prediction scores (81% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: cholesterol-ester transfer protein deficiency, coronary artery disorder, metabolic syndrome, age-related macular degeneration, macular degeneration, Decreased HDL cholesterol concentration, Hypercholesterolemia, metabolic disease, hyperlipidemia, coronary atherosclerosis, familial lipoprotein lipase deficiency, physical activity.
Protein structure and variant hotspots
- Protein features: 4 post-translational modification sites.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CETP variants
Examples include L2V, L2L, A3P, A3T, A4S, T5K, T5S, T5A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L2V (p.Leu2Val), gnomAD rs2056025839, REVEL 0.06, CADD 14.30
- L2L (p.Leu2Leu), rs2056025839, gnomAD 16-56961983-C-T, CADD 5.92
- A3P (p.Ala3Pro), gnomAD rs1181043392, REVEL 0.11, CADD 17.30
- A3T (p.Ala3Thr), gnomAD 16-56961986-G-A, REVEL 0.02, CADD 16.80
- A4S (p.Ala4Ser), gnomAD 16-56961989-G-T, REVEL 0.04, CADD 13.00
- T5K (p.Thr5Lys), ESP rs146270725, ExAC rs146270725
- T5S (p.Thr5Ser), rs766825140, gnomAD 16-56961990-CCA-C, CADD 16.40
- T5A (p.Thr5Ala), gnomAD 16-56961992-A-G, REVEL 0.01, CADD 3.16
- T5T (p.Thr5Thr), rs1418803684, gnomAD 16-56961994-A-T, CADD 1.14
- V6D (p.Val6Asp), rs34119551, ClinGen CA8070729, ClinVar RCV003548572, 1000Genomes rs34119551, REVEL 0.68, CADD 18.60, Likely benign, not provided
- V6V (p.Val6Val), gnomAD 16-56961997-C-A, CADD 3.84
- T8I (p.Thr8Ile), rs991188482, ClinGen CA281516602, ClinVar RCV003388677, ClinVar RCV005104280, REVEL 0.03, CADD 7.80, Uncertain significance, not specified; Hyperalphalipoproteinemia 1; not provided
- T8N (p.Thr8Asn), TOPMed rs991188482, gnomAD rs991188482, REVEL 0.03, CADD 8.46, Uncertain significance
- T8S (p.Thr8Ser), TOPMed rs991188482, gnomAD rs991188482, REVEL 0.03, CADD 7.26, Uncertain significance
- A10V (p.Ala10Val), gnomAD 16-56962008-C-T, REVEL 0.04, CADD 15.70
- A10A (p.Ala10Ala), rs762643341, gnomAD 16-56962009-C-T, CADD 8.20
- L11P (p.Leu11Pro), NCI-TCGA Cosmic COSV5236, cosmic curated COSV52362, Variant assessed as somatic; moderate impact.
- L11L (p.Leu11Leu), rs914182923, gnomAD 16-56962010-C-T, CADD 7.57
- L12R (p.Leu12Arg), gnomAD rs1403262620, REVEL 0.27, CADD 23.10
- L12V (p.Leu12Val), gnomAD 16-56962013-C-G, REVEL 0.09, CADD 16.60
- L12L (p.Leu12Leu), rs1460617147, gnomAD 16-56962013-C-T, CADD 8.62
- G13V (p.Gly13Val), gnomAD 16-56962017-G-T, REVEL 0.18, CADD 22.70
- N14I (p.Asn14Ile), gnomAD rs1467127265
- N14N (p.Asn14Asn), rs763683938, gnomAD 16-56962021-T-C, CADD 4.42
- A15D (p.Ala15Asp), 1000Genomes rs34065661, ESP rs34065661, ExAC rs34065661, TOPMed rs34065661, REVEL 0.06, AlphaMissense 0.08, Benign
- A15G (p.Ala15Gly), rs34065661, ClinGen CA8070732, ClinVar RCV000371616, ClinVar RCV000966006, REVEL 0.01, AlphaMissense 0.08, Benign, not specified; not provided; Hyperalphalipoproteinemia 1
- A15S (p.Ala15Ser), rs2543633239, ClinGen CA395995683, ClinVar RCV004153750, Uncertain significance, not specified
- A15V (p.Ala15Val), rs34065661, ClinGen CA395995695, ClinVar RCV004153753, AlphaMissense 0.08, MetaLR 0.00, Likely benign, not specified
- A15T (p.Ala15Thr), gnomAD 16-56962022-G-A, REVEL 0.03, CADD 10.60
- A15A (p.Ala15Ala), gnomAD 16-56962024-C-G, CADD 7.22
- H16N (p.His16Asn), gnomAD rs1389424544, REVEL 0.02, CADD 3.20
- H16R (p.His16Arg), gnomAD rs1303090767, REVEL 0.02, CADD 2.59
- H16H (p.His16His), rs767475225, gnomAD 16-56962027-T-C, CADD 0.65
- A17V (p.Ala17Val), gnomAD 16-56962029-C-T, REVEL 0.05, CADD 22.70
- C18S (p.Cys18Ser), gnomAD 16-56962031-T-A, REVEL 0.04, CADD 12.80
- C18C (p.Cys18Cys), rs200386961, gnomAD 16-56962033-C-T, CADD 5.58
- S19P (p.Ser19Pro), gnomAD 16-56962034-T-C, REVEL 0.02, CADD 9.44
- S19Y (p.Ser19Tyr), gnomAD 16-56962035-C-A, REVEL 0.07, CADD 17.80
- S19C (p.Ser19Cys), gnomAD 16-56962035-C-G, REVEL 0.06, CADD 15.70
- K20K (p.Lys20Lys), rs750401042, gnomAD 16-56962039-A-G, CADD 2.73
- G21D (p.Gly21Asp), gnomAD rs1282799611, REVEL 0.07, CADD 2.69
- G21V (p.Gly21Val), gnomAD rs1282799611, REVEL 0.03, CADD 4.88
- G21A (p.Gly21Ala), gnomAD 16-56962036-CA-C, CADD 16.10
- G21G (p.Gly21Gly), gnomAD 16-56962042-C-T, CADD 1.30
- T22I (p.Thr22Ile), gnomAD 16-56962044-C-T, REVEL 0.02, CADD 7.66
- T22T (p.Thr22Thr), rs5884, gnomAD 16-56962045-C-A, CADD 2.29
- S23L (p.Ser23Leu), rs574035014, ClinGen CA8070737, ClinVar RCV003871811, 1000Genomes rs574035014, REVEL 0.01, CADD 2.44, Uncertain significance, not provided
- S23S (p.Ser23Ser), rs753665779, gnomAD 16-56962048-G-A, CADD 0.35
- H24Q (p.His24Gln), ESP rs148628525, ExAC rs148628525, TOPMed rs148628525, gnomAD rs148628525, REVEL 0.01, CADD 0.01
- H24R (p.His24Arg), gnomAD 16-56962050-A-G, REVEL 0.00, CADD 0.41
- H24H (p.His24His), rs148628525, gnomAD 16-56962051-C-T, CADD 0.10
- E25K (p.Glu25Lys), rs201234837, ClinGen CA8070741, cosmic curated COSV52361, ClinVar RCV003777090, REVEL 0.00, CADD 0.22, Conflicting interpretations, not provided; not specified
- A26S (p.Ala26Ser), gnomAD 16-56962055-G-T, REVEL 0.08, CADD 8.05
- A26E (p.Ala26Glu), gnomAD 16-56962056-C-A, REVEL 0.18, CADD 15.70
- G27R (p.Gly27Arg), Ensembl rs2141989701, REVEL 0.26, CADD 23.30
- I28M (p.Ile28Met), 1000Genomes rs142117489, ESP rs142117489, ExAC rs142117489, TOPMed rs142117489, REVEL 0.27, CADD 9.87, Benign
- I28V (p.Ile28Val), ExAC rs772113814, TOPMed rs772113814, gnomAD rs772113814, REVEL 0.12, CADD 19.80, Uncertain significance, not specified
- I28F (p.Ile28Phe), gnomAD 16-56962061-A-T, REVEL 0.18, CADD 23.60
- I28I (p.Ile28Ile), rs142117489, gnomAD 16-56962063-C-T, CADD 1.38
- V29E (p.Val29Glu), gnomAD rs2056027061, REVEL 0.26, CADD 24.60
- V29L (p.Val29Leu), ExAC rs747564264, TOPMed rs747564264, gnomAD rs747564264, REVEL 0.21, CADD 22.90, Uncertain significance
- V29M (p.Val29Met), rs747564264, ClinGen CA8070744, ClinVar RCV003863428, ExAC rs747564264, REVEL 0.23, CADD 23.30, Uncertain significance, not provided
- V29V (p.Val29Val), gnomAD 16-56962066-G-A, CADD 7.23
- C30Y (p.Cys30Tyr), rs771585518, ClinGen CA8070745, ClinVar RCV001771253, ExAC rs771585518, REVEL 0.20, CADD 23.70, Conflicting interpretations, not provided
- R31C (p.Arg31Cys), rs777093455, ClinGen CA8070746, ClinVar RCV001904293, ExAC rs777093455, REVEL 0.26, CADD 23.60, Uncertain significance, not provided
- R31H (p.Arg31His), rs147758502, ClinGen CA8070747, cosmic curated COSV99059, ClinVar RCV000389076, REVEL 0.24, CADD 23.60, Uncertain significance, not specified; not provided; Hyperalphalipoproteinemia 1
- R31P (p.Arg31Pro), ESP rs147758502, ExAC rs147758502, TOPMed rs147758502, gnomAD rs147758502, REVEL 0.36, CADD 24.40, Uncertain significance
- R31A (p.Arg31Ala), gnomAD 16-56962068-GC-G, CADD 22.80
- R31L (p.Arg31Leu), gnomAD 16-56962071-G-T, REVEL 0.28, CADD 23.80
- I32V (p.Ile32Val), gnomAD rs1460379451
- I32S (p.Ile32Ser), gnomAD 16-56962074-T-G, REVEL 0.35, CADD 24.70
- T33I (p.Thr33Ile), gnomAD 16-56962077-C-T, REVEL 0.19, CADD 23.40
- K34T (p.Lys34Thr), gnomAD 16-56962080-A-C, REVEL 0.12, CADD 21.80
- P35T (p.Pro35Thr), gnomAD 16-56962082-C-A, REVEL 0.11, CADD 19.80
- P35P (p.Pro35Pro), rs768295149, gnomAD 16-56962084-T-C, CADD 7.83
- A36T (p.Ala36Thr), TOPMed rs1365954946, gnomAD rs1365954946, REVEL 0.22, CADD 25.10
- A36S (p.Ala36Ser), gnomAD 16-56962085-G-T, REVEL 0.20, CADD 24.40
- A36D (p.Ala36Asp), gnomAD 16-56962086-C-A, REVEL 0.34, CADD 24.20
- A36A (p.Ala36Ala), gnomAD 16-56962087-C-G, CADD 6.42
- L37F (p.Leu37Phe), ExAC rs773933829, gnomAD rs773933829, REVEL 0.05, CADD 11.70
- L37L (p.Leu37Leu), rs1302718246, gnomAD 16-56962090-C-G, CADD 5.36
- L38P (p.Leu38Pro), ExAC rs761381765, gnomAD rs761381765, REVEL 0.20, CADD 24.80
- L38Q (p.Leu38Gln), ExAC rs761381765, gnomAD rs761381765, REVEL 0.13, CADD 25.00
- L38L (p.Leu38Leu), gnomAD 16-56962091-C-T, CADD 4.75
- V39L (p.Val39Leu), ExAC rs766986850, TOPMed rs766986850, gnomAD rs766986850, REVEL 0.08, CADD 17.10, Uncertain significance, not provided
- V39M (p.Val39Met), gnomAD 16-56962094-G-A, REVEL 0.09, CADD 23.80
- V39E (p.Val39Glu), gnomAD 16-56962095-T-A, REVEL 0.22, CADD 23.10
- V39V (p.Val39Val), gnomAD 16-56962096-G-T, CADD 11.80
- L40S (p.Leu40Ser), TOPMed rs2056035729
- L40L (p.Leu40Leu), rs2056027530, gnomAD 16-56962097-T-C, CADD 18.70
- L40F (p.Leu40Phe), gnomAD 16-56963011-G-T, REVEL 0.22, CADD 23.80
- N41S (p.Asn41Ser), NCI-TCGA Cosmic COSV5236, cosmic curated COSV52363, Variant assessed as somatic; moderate impact.
- N41Y (p.Asn41Tyr), gnomAD 16-56963012-A-T, REVEL 0.33, CADD 24.00
- H42Q (p.His42Gln), rs776857859, ExAC rs776857859, TOPMed rs776857859, gnomAD rs776857859, REVEL 0.12, CADD 4.06, Uncertain significance, not provided
- H42H (p.His42His), rs776857859, gnomAD 16-56963017-C-T, CADD 1.98
- E43* (p.Glu43Ter), NCI-TCGA TCGA novel, CADD 35.00, Variant assessed as somatic; high impact.
- E43K (p.Glu43Lys), ESP rs141121785, ExAC rs141121785, TOPMed rs141121785, gnomAD rs141121785, REVEL 0.18, CADD 18.40, Uncertain significance, not provided
- E43Q (p.Glu43Gln), gnomAD 16-56963018-G-C, REVEL 0.09, CADD 17.60
- E43E (p.Glu43Glu), gnomAD 16-56963020-G-A, CADD 5.22
- T44I (p.Thr44Ile), TOPMed rs1283371747, gnomAD rs1283371747, REVEL 0.23, CADD 22.60
- T44T (p.Thr44Thr), gnomAD 16-56963023-T-A, CADD 4.49
- A45T (p.Ala45Thr), gnomAD rs1221637651, REVEL 0.02, CADD 3.37
- A45V (p.Ala45Val), rs200956328, NCI-TCGA Cosmic COSV9956, cosmic curated COSV99569, ExAC rs200956328, REVEL 0.06, CADD 19.90, Variant assessed as somatic; moderate impact.
- A45A (p.Ala45Ala), rs1438295846, gnomAD 16-56963026-C-T, CADD 5.20
- K46E (p.Lys46Glu), cosmic curated COSV99569, ExAC rs775077692, TOPMed rs775077692, gnomAD rs775077692, REVEL 0.07, CADD 14.20, Uncertain significance, not specified; not provided
- K46Q (p.Lys46Gln), ExAC rs775077692, TOPMed rs775077692, gnomAD rs775077692, REVEL 0.05, CADD 12.00
- K46R (p.Lys46Arg), TOPMed rs1230953022, gnomAD rs1230953022, REVEL 0.05, CADD 19.40
- K46K (p.Lys46Lys), gnomAD 16-56963029-G-A, CADD 3.53
- V47M (p.Val47Met), ExAC rs762853056, gnomAD rs762853056
- V47G (p.Val47Gly), gnomAD 16-56963031-T-G, REVEL 0.18, CADD 23.20
- V47V (p.Val47Val), rs764397238, gnomAD 16-56963032-G-T, CADD 3.03
- I48M (p.Ile48Met), 1000Genomes rs202133505, TOPMed rs202133505, gnomAD rs202133505, REVEL 0.14, CADD 20.10
- Q49P (p.Gln49Pro), Ensembl rs2056036157, REVEL 0.22, CADD 22.70
- Q49* (p.Gln49Ter), gnomAD 16-56963036-C-T, CADD 35.00
- T50I (p.Thr50Ile), TOPMed rs1294649999, gnomAD rs1294649999, REVEL 0.06, CADD 18.50, Uncertain significance, not specified
- T50T (p.Thr50Thr), rs751896271, gnomAD 16-56963041-C-T, CADD 0.16
- A51S (p.Ala51Ser), rs549487844, NCI-TCGA Cosmic COSV9956, cosmic curated COSV99569, NCI-TCGA Cosmic COSV9957, REVEL 0.15, CADD 20.90, Variant assessed as somatic; moderate impact.
- A51T (p.Ala51Thr), rs549487844, NCI-TCGA Cosmic COSV9956, NCI-TCGA Cosmic COSV9957, cosmic curated COSV99570, REVEL 0.17, CADD 22.00, Variant assessed as somatic; moderate impact.
- A51G (p.Ala51Gly), gnomAD 16-56963043-C-G, REVEL 0.14, CADD 18.90
- A51D (p.Ala51Asp), gnomAD 16-56963043-C-A, REVEL 0.16, CADD 20.50
- F52L (p.Phe52Leu), 1000Genomes rs201282006, ExAC rs201282006, gnomAD rs201282006, REVEL 0.20, CADD 22.80
- F52S (p.Phe52Ser), Ensembl rs1596993361
- Q53* (p.Gln53Ter), gnomAD rs1410995889, CADD 34.00
- Q53H (p.Gln53His), ESP rs373088967, ExAC rs373088967, TOPMed rs373088967, gnomAD rs373088967
- Q53Q (p.Gln53Gln), rs373088967, gnomAD 16-56963050-G-A, CADD 2.60
- R54* (p.Arg54Ter), rs780627434, ClinGen CA8070807, cosmic curated COSV52364, ClinVar RCV001780766, CADD 26.60, Likely pathogenic
- R54P (p.Arg54Pro), ExAC rs755405744, TOPMed rs755405744, gnomAD rs755405744, REVEL 0.13, CADD 15.60, Uncertain significance, not provided
- R54Q (p.Arg54Gln), ExAC rs755405744, TOPMed rs755405744, gnomAD rs755405744, REVEL 0.10, CADD 11.20
- R54R (p.Arg54Arg), rs780627434, gnomAD 16-56963051-C-A, CADD 0.70
- S56I (p.Ser56Ile), NCI-TCGA Cosmic COSV9957, cosmic curated COSV99570, Variant assessed as somatic; moderate impact.
- S56R (p.Ser56Arg), TOPMed rs1344354869, gnomAD rs1344354869, REVEL 0.04, CADD 6.93, Uncertain significance, not specified
- S56A (p.Ser56Ala), rs753876598, gnomAD 16-56963054-GC-G, CADD 13.50
- S56N (p.Ser56Asn), gnomAD 16-56963058-G-A, REVEL 0.01, CADD 0.37
- S56S (p.Ser56Ser), rs1344354869, gnomAD 16-56963059-C-T, CADD 5.34
- Y57* (p.Tyr57Ter), gnomAD 16-56963062-C-G, CADD 34.00
- P58R (p.Pro58Arg), gnomAD rs890161478, REVEL 0.40, CADD 22.70
- P58L (p.Pro58Leu), gnomAD 16-56963063-CCAGA, CADD 22.80
- P58S (p.Pro58Ser), gnomAD 16-56963063-C-T, REVEL 0.33, CADD 19.80
- D59H (p.Asp59His), TOPMed rs1271404748, gnomAD rs1271404748, REVEL 0.10, CADD 19.20
- I60* (p.Ile60Ter), gnomAD 16-56963068-TATCA, CADD 24.50
- I60I (p.Ile60Ile), gnomAD 16-56963071-C-T, CADD 6.36
- T61M (p.Thr61Met), rs142464301, ClinGen CA8070811, ClinVar RCV001899560, ClinVar RCV002490063, REVEL 0.66, CADD 17.20, Uncertain significance, not provided; Hyperalphalipoproteinemia 1
- T61P (p.Thr61Pro), gnomAD 16-56963072-A-C, REVEL 0.03, CADD 17.20
- T61T (p.Thr61Thr), rs746717309, gnomAD 16-56963074-G-A, CADD 1.77
- G62S (p.Gly62Ser), Ensembl rs2056036743, REVEL 0.34, CADD 23.30
- G62G (p.Gly62Gly), rs376596539, gnomAD 16-56963077-C-T, CADD 7.28
- E63K (p.Glu63Lys), 1000Genomes rs745384723, ExAC rs745384723, TOPMed rs745384723, gnomAD rs745384723, REVEL 0.15, CADD 16.00, Uncertain significance, not specified
- E63Q (p.Glu63Gln), gnomAD 16-56963078-G-C, REVEL 0.15, CADD 17.30
- K64E (p.Lys64Glu), ExAC rs769557581, gnomAD rs769557581, REVEL 0.10, CADD 20.00
- K64R (p.Lys64Arg), rs2543635386, ClinGen CA395996794, ClinVar RCV003868307, REVEL 0.06, CADD 10.30, Uncertain significance, not provided
- A65P (p.Ala65Pro), rs369294786, ClinGen CA8070817, ClinVar RCV002045198, ESP rs369294786, REVEL 0.10, CADD 12.80, Uncertain significance, not provided
- A65T (p.Ala65Thr), gnomAD 16-56963084-G-A, REVEL 0.03, CADD 5.43
- M66K (p.Met66Lys), ExAC rs764019349, TOPMed rs764019349, gnomAD rs764019349
- M66L (p.Met66Leu), ExAC rs762836445, TOPMed rs762836445, gnomAD rs762836445
- M66R (p.Met66Arg), ExAC rs764019349, TOPMed rs764019349, gnomAD rs764019349
- M66T (p.Met66Thr), ExAC rs764019349, TOPMed rs764019349, gnomAD rs764019349
- M66V (p.Met66Val), ExAC rs762836445, TOPMed rs762836445, gnomAD rs762836445
- M67K (p.Met67Lys), rs762087842, ClinGen CA8070821, ClinVar RCV004089050, ExAC rs762087842, REVEL 0.03, CADD 1.53, Uncertain significance, not specified
- M67R (p.Met67Arg), ExAC rs762087842, TOPMed rs762087842, gnomAD rs762087842, Uncertain significance
- M67V (p.Met67Val), gnomAD rs1243908679, REVEL 0.00, CADD 0.12
- L68F (p.Leu68Phe), gnomAD 16-56963093-C-T, REVEL 0.01, CADD 0.21
- L68L (p.Leu68Leu), gnomAD 16-56963095-C-G, CADD 0.70
- L69F (p.Leu69Phe), gnomAD 16-56963096-C-T, REVEL 0.13, CADD 17.60
- L69L (p.Leu69Leu), gnomAD 16-56963098-T-C, CADD 2.49
- G70S (p.Gly70Ser), gnomAD 16-56963099-G-A, REVEL 0.39, CADD 23.50
- G70G (p.Gly70Gly), rs1299345886, gnomAD 16-56963101-C-T, CADD 2.46
- Q71E (p.Gln71Glu), TOPMed rs2056037031
- Q71R (p.Gln71Arg), NCI-TCGA Cosmic COSV5236, cosmic curated COSV52364, Variant assessed as somatic; moderate impact.
- Q71L (p.Gln71Leu), gnomAD 16-56963103-A-T, REVEL 0.02, CADD 11.00
- V72I (p.Val72Ile), ExAC rs767785661, TOPMed rs767785661, gnomAD rs767785661, REVEL 0.21, CADD 13.70, Uncertain significance
- V72L (p.Val72Leu), rs767785661, ClinGen CA10647850, ClinVar RCV000296497, ExAC rs767785661, REVEL 0.23, CADD 17.60, Uncertain significance, Hyperalphalipoproteinemia 1
- V72V (p.Val72Val), rs750412877, gnomAD 16-56963107-C-G, CADD 1.42
- K73T (p.Lys73Thr), gnomAD 16-56963109-A-C, REVEL 0.02, CADD 3.81
- K73K (p.Lys73Lys), gnomAD 16-56963110-G-A, CADD 0.89
- Y74* (p.Tyr74Ter), ExAC rs201790757, TOPMed rs201790757, gnomAD rs201790757, CADD 25.50
- Y74D (p.Tyr74Asp), TOPMed rs769982955
- Y74H (p.Tyr74His), TOPMed rs769982955
- Y74C (p.Tyr74Cys), gnomAD 16-56963112-A-G, REVEL 0.37, CADD 22.40
- G75E (p.Gly75Glu), Ensembl rs2056037252
- G75R (p.Gly75Arg), 1000Genomes rs766793959, ExAC rs766793959, gnomAD rs766793959, REVEL 0.13, CADD 19.60
Public CETP analysis runs
- CETP analysis run — CETP (824 variants) — completed 2026-08-19